Sector News

Teva Pharm says media reports of up to 6,000 layoffs incorrect

March 27, 2017
Life sciences

Teva Pharmaceutical Industries’ plans to end unprofitable activities and freeze recruitment, but said Israeli media reports of up to 6,000 layoffs were incorrect.

Earlier on Thursday, two of Israel’s leading financial news websites carried separate reports that Teva, the world’s biggest generic drug maker and Israel’s largest company, planned to fire between 2,000 and 6,000 workers – or as much as 11 percent of the workforce.

A Teva spokesperson had initially declined to comment on the report, but the company later put out a statement saying the figures the media gave were inaccurate.

“The efficiency program is an integral part of Teva’s business reality. The program includes, among other things, ending unprofitable activities and consolidating functions, in addition to freezing recruitment and natural employee turnover,” the company said.

“These processes are conducted through a continuous open dialogue with the employees. This will be the practice, including in Israel, as necessary. We would like to stress that the numbers which were published in the media are incorrect,” it said.

Teva employs around 57,000 people globally.

It has had a rough year, though, with a series of costly acquisitions, along with delayed drug launches, sending its stock plummeting 72 percent to $32.61 the past 12 months.

That forced former chief executive Erez Vigodman to step down in February, with Chairman Yitzhak Peterburg replacing him on a temporary basis.

One of the websites, Calcalist, said Teva has already reduced its workforce in Israel by around 100 people as part of the efficiency plan.

By Ari Rabinovitch and Steven Scheer

Source: Reuters

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).